. 2020 Apr 21;158(3):913–922. doi: 10.1016/j.chest.2020.04.011

Table 3.

Selected Ongoing Clinical Trials in the Prevention of Asthma

Trial Number	Study Design	Primary Outcome of Study
NCT02148796 ⁵³	Double-blind, RCT of Broncho-Vaxom vs placebo for 10 d/mo for 2 y in children 6-18 mo old at high risk of asthma. Followed by observation year.	Time to LRTI with wheeze in the third year of study.
NCT02570984 ¹⁰	Double-blind RCT of omalizumab vs placebo every 4 wks for 2 y starting at 24-47 mo of age in wheezing children at high risk of asthma because of sensitization to aeroallergens.	Asthma diagnosis during the second of 2 y of observation.
NCT02624947 ⁵⁸	Observer-blind, RCT of RSV F vaccine vs placebo in 4,636 third-trimester pregnant women. Maternal subjects studied for ∼ 9 mo after the first dose and the infant studied for 1 y of life.	Incidence of significant RSV LRTI (hypoxia or tachypnea) in the first 90 d of life. Also evaluating wheeze in the first year.
NCT02878330 ⁵⁸	Double-blind, RCT evaluating MEDI8897, an anti-RSV monoclonal antibody with an extended half-life in healthy preterm infants.	Number of infants hospitalized with LRTI due to RSV.
NCT02911935 ¹¹	Double-blind RCT of children aged 1-18 mo hospitalized with RSV bronchiolitis and treated with azithromycin vs placebo × 2 wks and observed for up to 48 mo.	Occurrence of recurrent wheeze during preschool years.
U1111-1203-1961⁶⁴	RCT of infants randomized to receive either exclusively paracetamol vs ibuprofen prn fever/pain in the first year of life and asthma rates evaluated.	Asthma diagnosis at age 6.

LRTI = lower respiratory tract infection; RSV = respiratory syncytial virus. See Table 1 legend for expansion of other abbreviations.